Synthon (rights of glatiramer acetate) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Synthon (rights of glatiramer acetate) General Information


The commercialization rights of glatiramer acetate in the United States. It is a potential generic version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS).

Contact Information

Ownership Status
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Primary Office
  • P.O. Box 110487
  • Research Triangle Park
  • Durham, NC 27709
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synthon (rights of glatiramer acetate) Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Synthon (rights of glatiramer acetate)‘s full profile, request access.

Request a free trial